Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Oct 8;62(15):1339-42.
doi: 10.1016/j.jacc.2013.07.010. Epub 2013 Jul 31.

Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter

Sanjiv J Shah  1
Affiliations
Editorial

Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter

Sanjiv J Shah. J Am Coll Cardiol. .
No abstract available

Keywords: diastolic heart failure; heart rate; ivabradine; randomized controlled trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Teoretical Schema of Heart Failure with Preserved Ejection Fraction Patient Types with Sample Patients, Risk Profiles, and Matched Therapies HTN = hypertension; NYHA = New York Heart Association functional class; HF = heart failure; LVEF = left ventricular ejection fraction; LAE = left atrial enlargement; DD = diastolic dysfunction; PASP = pulmonary artery systolic pressure; E/e’ = ratio of early mitral inflow to early mitral annular diastolic tissue velocity; CAD s/p CABG = coronary artery disease status-post coronary artery bypass grafting; DOE = dyspnea on exertion; MR = mitral regurgitation; AR = aortic regurgitation; DM2 = type 2 diabetes mellitus; CKD = chronic kidney disease; SOB = shortness of breath; RVH = right ventricular hypertrophy; RV = right ventricular; BNP = B-type natriuretic peptide; If = inward “funny” channel; MRA = mineralocorticoid receptor antagonist; ARNI = angiotensin receptor / neprilysin inhibitor; PDE5 = phosphodiesterase-5
See this image and copyright information in PMC

Comment on

References

    1. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126:65–75. - PubMed
    1. Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6:184–92. - PMC - PubMed
    1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9. - PubMed
    1. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005. - PMC - PubMed
    1. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA. 2008;300:431–3. - PubMed